Novavax Inc Stock Price, News & Analysis

Novavax (Nasdaq: NVAX) announced its participation in five investor conferences, highlighting its COVID-19 vaccine candidate NVX-CoV2373. Key events include:

• Citi 15th Annual BioPharma Virtual Conference on September 10, 2020
• H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, 9:30 a.m. ET
• Cantor Virtual Global Healthcare Conference on September 15, 2020, 11:20 a.m. ET
• Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 16, 2020, 12:30 p.m. ET
• Leerink CyberRx Series: Vaccine Forum on September 23, 2020, 9:00 a.m. ET

Replays will be available on Novavax's website.

Novavax (Nasdaq: NVAX) announced the publication of Phase 1 data for its COVID-19 vaccine candidate, NVX-CoV2373, in The New England Journal of Medicine. The results indicate a strong safety profile and superior antibody responses compared to human convalescent sera. Following positive Phase 1 results, multiple Phase 2 trials commenced in the US, Australia, and South Africa to further evaluate efficacy. The funding for the trial includes support from the Coalition for Epidemic Preparedness Innovations (CEPI). NVX-CoV2373 showcases a favorable product profile, with stability for easy storage.

Novavax (NVAX) has reached an agreement with the Canadian government to supply up to 76 million doses of its COVID-19 vaccine, NVX-CoV2373, set to start in the second quarter of 2021. The deal aims to ensure broad access to the vaccine, which is currently in multiple Phase 2 clinical trials, including a Phase 2b trial in South Africa. NVX-CoV2373 utilizes Novavax's proprietary Matrix-M™ adjuvant to enhance immune responses. The agreement will finalize subject to Health Canada's licensure of the vaccine.

Novavax (Nasdaq: NVAX) announced the enrollment of first volunteers in the Phase 2 clinical trial of its COVID-19 vaccine candidate, NVX-CoV2373. This trial aims to assess immunogenicity and safety, expanding the age range to include participants aged 60-84 years, who constitute about 50% of the trial population. The trial will enroll up to 1,500 volunteers across the U.S. and Australia, with preliminary efficacy evaluations as a secondary objective. Interim data is expected in Q4 2020, following encouraging Phase 1 results that showed robust antibody responses.

Novavax, Inc. (NASDAQ: NVAX) has announced the initiation of a Phase 2b clinical trial in South Africa for its COVID-19 vaccine candidate NVX-CoV2373. The trial, led by Professor Shabir Madhi, aims to assess the vaccine's efficacy with a $15 million grant from the Bill & Melinda Gates Foundation. Approximately 2,665 healthy adults and 240 medically stable, HIV-positive adults will participate. The trial infrastructure and seasonal COVID-19 transmission could allow for rapid evaluation of efficacy. If successful, the vaccine may be supplied to South Africa through Novavax's collaboration with the Serum Institute of India.

Novavax has signed an agreement with the UK government to supply 60 million doses of its COVID-19 vaccine, NVX-CoV2373, starting in Q1 2021. The partnership includes collaboration with FUJIFILM Diosynth Biotechnologies to manufacture the vaccine's antigen in the UK, with a capacity of up to 180 million doses annually. A Phase 3 clinical trial will assess the vaccine's efficacy, involving approximately 9,000 adults, slated to begin in Q3 2020. Novavax has received $2 billion in funding for its global vaccine program.

AGC Biologics has expanded its partnership with Novavax (NASDAQ: NVAX), enhancing the production of Matrix-M, the adjuvant for Novavax's coronavirus vaccine, NVX-CoV2373. The manufacturing will occur at AGC's facilities in Seattle and Copenhagen to ensure adequate supply for the U.S. and global markets. This development supports Novavax's urgent need to enhance vaccine availability in 2020 and 2021. Both companies acknowledge the critical role AGC plays in the supply chain for the coronavirus vaccine.

Novavax (NVAX) reported encouraging Phase 1 data for its COVID-19 vaccine, NVX-CoV2373, demonstrating superior neutralization levels and strong immune responses. The company secured $2 billion funding from CEPI, DoD, and OWS, enhancing its operational capacity and collaborations with Takeda and Serum Institute. Financial results show a significant revenue increase to $35.5 million for Q2 2020, compared to $3.4 million in Q2 2019, alongside a reduced net loss of $17.5 million. Novavax continues to strengthen its leadership team and expand manufacturing capabilities for vaccine production.

Novavax has partnered with Takeda to license its COVID-19 vaccine technology, NVX-CoV2373, for production and commercialization in Japan. The Government of Japan will fund Takeda for technology transfer and infrastructure setup, enabling the manufacture of over 250 million doses annually. Novavax will supply the proprietary Matrix-M adjuvant. The collaboration aims to enhance pandemic preparedness and expand vaccine availability in Japan, with Novavax set to receive milestone payments and a share of the vaccine proceeds.